Image de couverture de livre

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Luciano Revelli, Melisa Dirchwolf
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
par: Marcus M. Mücke, et autres
Publié: (2024)

Editorial: Terlipressin Induced Bradycardia
par: Nancy Reau, et autres
Publié: (2025)

Letter: Is Routine ECG Monitoring Redundant During Terlipressin Therapy in HRS ‐ AKI ?
par: Xing Wang
Publié: (2025)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
par: Ming‐Lun Yeh, et autres
Publié: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
par: Linda Henry, et autres
Publié: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
par: Lukas Hartl, et autres
Publié: (2024)

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis
par: Dominik Bettinger, et autres
Publié: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
par: Haibo Jing, et autres
Publié: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
par: Andrea Martini, et autres
Publié: (2024)

Letter: Association between terlipressin and multi‐drug‐resistant organism rectal colonisation
par: Katrina Tan, et autres
Publié: (2024)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
par: Elliot B. Tapper, et autres
Publié: (2024)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
par: Ling Yang, et autres
Publié: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
par: Mingsi Zhang, et autres
Publié: (2024)

Review article: Evaluation and care of the critically ill patient with cirrhosis
par: Iva Kosuta, et autres
Publié: (2024)

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies
par: Jasmohan S. Bajaj, et autres
Publié: (2025)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
par: Elliot B. Tapper, et autres
Publié: (2024)

Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
par: Danielle Adebayo, et autres
Publié: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
par: Senlin Ye, et autres
Publié: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
par: Jian Wang, et autres
Publié: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
par: Leya Nedumannil, et autres
Publié: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
par: Lisa Sandmann, et autres
Publié: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
par: Lana Bridi, et autres
Publié: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
par: Lukas Burghart, et autres
Publié: (2024)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
par: Harris Siddiqi, et autres
Publié: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
par: Sagnik Biswas, et autres
Publié: (2024)

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score
par: Ting Wang, et autres
Publié: (2024)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
par: Philippe Sultanik, et autres
Publié: (2024)

Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study
par: Rahul Kumar, et autres
Publié: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
par: Mohamed I. Elsaid, et autres
Publié: (2024)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
par: Maryam Zafer, et autres
Publié: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
par: Jeongkuk Seo, et autres
Publié: (2024)

Editorial: Quantity is important!
par: Chee‐Kiat Tan
Publié: (2024)

Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis
par: Toshifumi Tada
Publié: (2025)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
par: Maxim S. Petrov
Publié: (2026)

Editorial: Plants against animals
par: Einar S. Björnsson
Publié: (2024)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
par: Manuel Barreiro‐de Acosta, et autres
Publié: (2024)

Editorial: Quantity is important! Authors' reply
par: Marika Rudler, et autres
Publié: (2024)

Editorial: Another brick in the CDST wall
par: Aurelien Amiot, et autres
Publié: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
par: Manjeet Kumar Goyal, et autres
Publié: (2026)

Editorial: Getting to the Heart of the Matter in IBD
par: Ashwin N. Ananthakrishnan
Publié: (2025)